Drug intelligence / Profile preview

Synprotec

Development stage: Unknown
Lead developer: Yakult Honsha
Modality: Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Synprotec is an oral synbiotic product developed by Yakult Honsha, comprising the probiotic *Bifidobacterium breve* strain Yakult and the prebiotic galacto-oligosaccharides. It is designed to optimize the gut microbiome environment, thereby enhancing systemic immune function and potentially improving the clinical outcomes of patients undergoing cancer treatment. Specifically, it is being evaluated in the CONCIERGE trial to determine if its administration alongside first-line immune checkpoint inhibitor-based therapy can improve progression-free survival in patients with unresectable or recurrent gastric or esophageal cancer.

Brand names: Synprotec
Other names: Synprotec synbiotics

Beyond the preview

Go deeper on Synprotec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synprotec.

Explore the full profile